Dr Giuseppe Galati (San Raffaele Scientific Institute, Milan, IT) discusses the DAPA-CKD study that was presented at ESC 2020.
This study evaluated the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.
Recorded remotely from Milan, 2020.
Recording Editor: Natascha Wienand
Editor: Mirjam Boros